{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:42:06Z","timestamp":1793911326988,"version":"4.8.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-03013-y","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:16:49Z","timestamp":1767028609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9158-1055","authenticated-orcid":false,"given":"Anna","family":"Nowak-Szwed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3324-9625","authenticated-orcid":false,"given":"Ceren","family":"Eyileten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2857-1986","authenticated-orcid":false,"given":"Zofia","family":"Wicik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7060-6775","authenticated-orcid":false,"given":"Sara","family":"Ahmadova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9280-4417","authenticated-orcid":false,"given":"Jeff","family":"Palatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6041-1635","authenticated-orcid":false,"given":"Jolanta","family":"Siller-Matula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9996-6128","authenticated-orcid":false,"given":"Dirk","family":"von Lewinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3510-9594","authenticated-orcid":false,"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-4458","authenticated-orcid":false,"given":"Marek","family":"Postula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"3013_CR1","doi-asserted-by":"publisher","unstructured":"Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes [Internet]. BMJ Open. 2012. p. e001007. Available from: https:\/\/doi.org\/10.1136\/bmjopen-2012-001007","DOI":"10.1136\/bmjopen-2012-001007"},{"key":"3013_CR2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review [Internet]. JACC Basic Transl Sci. 2020;5:632\u201344. https:\/\/doi.org\/10.1016\/j.jacbts.2020.02.004.","journal-title":"JACC Basic Transl Sci"},{"key":"3013_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4330\/wjc.v9.i5.407","volume":"9","author":"TJ Cahill","year":"2017","unstructured":"Cahill TJ, Kharbanda RK. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: mechanisms, incidence and identification of patients at risk [Internet]. World J Cardiol. 2017;9:407\u201315. https:\/\/doi.org\/10.4330\/wjc.v9.i5.407.","journal-title":"World J Cardiol"},{"key":"3013_CR4","doi-asserted-by":"publisher","unstructured":"Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial No-Reflow in Humans [Internet]. Journal of the American College of Cardiology. 2009. p. 281\u201392. Available from: https:\/\/doi.org\/10.1016\/j.jacc.2009.03.054","DOI":"10.1016\/j.jacc.2009.03.054"},{"key":"3013_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2012.10.002","volume":"1","author":"E Braunwald","year":"2013","unstructured":"Braunwald E. Heart failure [Internet]. JACC Heart Fail. 2013;1:1\u201320. https:\/\/doi.org\/10.1016\/j.jchf.2012.10.002.","journal-title":"JACC Heart Fail"},{"key":"3013_CR6","doi-asserted-by":"publisher","unstructured":"Lee SY, Lee TW, Park GT, Kim JH, Lee H-C, Han J-H, et al. Sodium\/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction [Internet]. Korean Circulation Journal. 2021. p. 251. Available from: https:\/\/doi.org\/10.4070\/kcj.2020.0303","DOI":"10.4070\/kcj.2020.0303"},{"key":"3013_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105788","volume":"161","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wu M, Xu J, Xu B, Kang L. Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice [Internet]. Eur J Pharm Sci. 2021;161:105788. https:\/\/doi.org\/10.1016\/j.ejps.2021.105788.","journal-title":"Eur J Pharm Sci"},{"key":"3013_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","volume":"4","author":"VG Lim","year":"2019","unstructured":"Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart [Internet]. JACC Basic Transl Sci. 2019;4:15\u201326. https:\/\/doi.org\/10.1016\/j.jacbts.2018.10.002.","journal-title":"JACC Basic Transl Sci"},{"key":"3013_CR9","doi-asserted-by":"publisher","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol [Internet]. 2019;73:1931\u201344. Available from: https:\/\/doi.org\/10.1016\/j.jacc.2019.01.056","DOI":"10.1016\/j.jacc.2019.01.056"},{"key":"3013_CR10","doi-asserted-by":"publisher","unstructured":"Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. Circulation [Internet]. 2020;142:1028\u201339. Available from: https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.045691","DOI":"10.1161\/CIRCULATIONAHA.120.045691"},{"key":"3013_CR11","doi-asserted-by":"publisher","unstructured":"Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y, et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial [Internet]. Available from: https:\/\/doi.org\/10.21203\/rs.3.rs-35207\/v2","DOI":"10.21203\/rs.3.rs-35207\/v2"},{"key":"3013_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1232583","volume":"2018","author":"K Batzias","year":"2018","unstructured":"Batzias K, Antonopoulos AS, Oikonomou E, Siasos G, Bletsa E, Stampouloglou PK, et al. Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis. J Diabetes Res. 2018;2018:1232583. https:\/\/doi.org\/10.1155\/2018\/1232583.","journal-title":"J Diabetes Res"},{"key":"3013_CR13","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1124\/jpet.118.253666","volume":"368","author":"H Oshima","year":"2019","unstructured":"Oshima H, Miki T, Kuno A, Mizuno M, Sato T, Tanno M, et al. Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and antioxidants in diabetic rats. J Pharmacol Exp Ther. 2019;368:524\u201334. https:\/\/doi.org\/10.1124\/jpet.118.253666.","journal-title":"J Pharmacol Exp Ther"},{"key":"3013_CR14","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ehf2.12336","volume":"5","author":"J Mustroph","year":"2018","unstructured":"Mustroph J, Wagemann O, L\u00fccht CM, Trum M, Hammer KP, Sag CM, et al. Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018;5:642\u20138. https:\/\/doi.org\/10.1002\/ehf2.12336.","journal-title":"ESC Heart Fail"},{"key":"3013_CR15","doi-asserted-by":"publisher","unstructured":"Yurista SR, Sillj\u00e9 HHW, Oberdorf-Maass SU, Schouten E-M, Pavez Giani MG, Hillebrands J-L, et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail [Internet]. 2019;21:862\u201373. Available from: https:\/\/doi.org\/10.1002\/ejhf.1473","DOI":"10.1002\/ejhf.1473"},{"key":"3013_CR16","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na\/H exchanger, lowering of cytosolic Na and vasodilation. Diabetologia. 2018;61:722\u20136. https:\/\/doi.org\/10.1007\/s00125-017-4509-7.","journal-title":"Diabetologia"},{"key":"3013_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.08.015","author":"DA Hess","year":"2019","unstructured":"Hess DA, Terenzi DC, Trac JZ, Quan A, Mason T, Al-Omran M, et al. SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. Cell Metab. 2019. https:\/\/doi.org\/10.1016\/j.cmet.2019.08.015.","journal-title":"Cell Metab"},{"key":"3013_CR18","doi-asserted-by":"publisher","unstructured":"Butler J, Schuyler Jones W, Udell JA, Anker SD, Petrie MC, Harrington J, et al. Empagliflozin after Acute Myocardial Infarction. New England Journal of Medicine [Internet]. 2024 [cited 2025 Sep 3]; Available from: https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa2314051","DOI":"10.1056\/NEJMoa2314051"},{"key":"3013_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.biopha.2018.09.079","volume":"108","author":"A Mihanfar","year":"2018","unstructured":"Mihanfar A, Nejabati HR, Fattahi A, Latifi Z, Faridvand Y, Pezeshkian M, et al. SIRT3-mediated cardiac remodeling\/repair following myocardial infarction. Biomed Pharmacother. 2018;108:367\u201373. https:\/\/doi.org\/10.1016\/j.biopha.2018.09.079.","journal-title":"Biomed Pharmacother"},{"key":"3013_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.07.030","author":"DC Rubinsztein","year":"2011","unstructured":"Rubinsztein DC, Mari\u00f1o G, Kroemer G. Autophagy and aging. Cell. 2011. https:\/\/doi.org\/10.1016\/j.cell.2011.07.030.","journal-title":"Cell"},{"key":"3013_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25054-y","volume":"8","author":"H Umino","year":"2018","unstructured":"Umino H, Hasegawa K, Minakuchi H, Muraoka H, Kawaguchi T, Kanda T, et al. High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci Rep. 2018;8:6791. https:\/\/doi.org\/10.1038\/s41598-018-25054-y.","journal-title":"Sci Rep"},{"key":"3013_CR22","doi-asserted-by":"publisher","DOI":"10.1042\/cs20190863","author":"MT Swe","year":"2019","unstructured":"Swe MT, Thongnak L, Jaikumkao K, Pongchaidecha A, Chatsudthipong V, Lungkaphin A. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. Clin Sci. 2019. https:\/\/doi.org\/10.1042\/cs20190863.","journal-title":"Clin Sci"},{"key":"3013_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28141","author":"J Kim","year":"2019","unstructured":"Kim J, Lee Y, You Y, Moon MK, Yoon K, Ahn Y, et al. Effect of sodium\u2010glucose cotransporter 2 inhibitor, empagliflozin, and \u03b1\u2010glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. J Cell Biochem. 2019. https:\/\/doi.org\/10.1002\/jcb.28141.","journal-title":"J Cell Biochem"},{"key":"3013_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0964-4","author":"Q Shao","year":"2019","unstructured":"Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019. https:\/\/doi.org\/10.1186\/s12933-019-0964-4.","journal-title":"Cardiovasc Diabetol"},{"key":"3013_CR25","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.119.045561","volume":"141","author":"M Packer","year":"2020","unstructured":"Packer M. Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance. Circulation. 2020;141:2095\u2013105. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.045561.","journal-title":"Circulation"},{"key":"3013_CR26","unstructured":"Nicolas FE. Role of ncRNAs in development, diagnosis and treatment of human cancer [Internet]. Recent patents on anti-cancer drug discovery. 2017. Available from: https:\/\/www.ingentaconnect.com\/content\/ben\/pra\/2017\/00000012\/00000002\/art00003"},{"key":"3013_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0892-5","volume":"17","author":"H Guo","year":"2016","unstructured":"Guo H, Liu J, Ben Q, Qu Y, Li M, Wang Y, et al. The aspirin-induced long non-coding RNA OLA1P2 blocks phosphorylated STAT3 homodimer formation. Genome Biol. 2016;17:24. https:\/\/doi.org\/10.1186\/s13059-016-0892-5.","journal-title":"Genome Biol"},{"key":"3013_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010358","author":"B Kura","year":"2020","unstructured":"Kura B, Szeiffova Bacova B, Kalocayova B, Sykora M, Slezak J. Oxidative stress-responsive microRNAs in heart injury. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21010358.","journal-title":"Int J Mol Sci"},{"key":"3013_CR29","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","volume":"43","author":"D von Lewinski","year":"2022","unstructured":"von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43:4421\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/ehac494.","journal-title":"Eur Heart J"},{"key":"3013_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/ejhf.2161","volume":"23","author":"G Strange","year":"2021","unstructured":"Strange G, Playford D, Scalia GM, Celermajer DS, Prior D, Codde J, et al. Change in ejection fraction and long-term mortality in adults referred for echocardiography. Eur J Heart Fail. 2021;23:555\u201363. https:\/\/doi.org\/10.1002\/ejhf.2161.","journal-title":"Eur J Heart Fail"},{"key":"3013_CR31","doi-asserted-by":"crossref","unstructured":"Wicik Z, Nowak A, Jarosz-Popek J, Wolska M, Eyileten C, Siller-Matula JM, et al. Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis. Front Pharmacol [Internet]. 2022 [cited 2024 Jul 30];13. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9421436\/","DOI":"10.3389\/fphar.2022.901340"},{"key":"3013_CR32","doi-asserted-by":"crossref","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res [Internet]. 2003 [cited 2024 Jul 31];13:2498. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC403769\/","DOI":"10.1101\/gr.1239303"},{"key":"3013_CR33","doi-asserted-by":"crossref","unstructured":"Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets. Nucleic Acids Res [Internet]. 2021 [cited 2024 Jul 31];49. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33237311\/","DOI":"10.1093\/nar\/gkab835"},{"key":"3013_CR34","doi-asserted-by":"crossref","unstructured":"Drost H-G, Paszkowski J. Biomartr: genomic data retrieval with R. Bioinformatics [Internet]. 2017 [cited 2024 Jul 31];33:1216\u20137. Available from: https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/33\/8\/1216\/49038570\/bioinformatics_33_8_1216.pdf","DOI":"10.1093\/bioinformatics\/btw821"},{"key":"3013_CR35","unstructured":"Pi\u00f1ero J, Ram\u00edrez-Anguita JM, Sa\u00fcch-Pitarch J, Ronzano F, Centeno E, Sanz F, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res [Internet]. 2019 [cited 2024 Jul 31];48:D845\u201355. Available from: https:\/\/academic.oup.com\/nar\/article-pdf\/48\/D1\/D845\/31697865\/gkz1021.pdf"},{"key":"3013_CR36","doi-asserted-by":"publisher","unstructured":"Palasca O, Santos A, Stolte C, Gorodkin J, Jensen LJ. TISSUES 2.0: an integrative web resource on mammalian tissue expression. Database (Oxford) [Internet]. 2018;2018. Available from: https:\/\/doi.org\/10.1093\/database\/bay028","DOI":"10.1093\/database\/bay028"},{"key":"3013_CR37","unstructured":"TISSUES [Internet]. [cited 2025 Jun 9]. Available from: https:\/\/tissues.jensenlab.org\/Downloads"},{"key":"3013_CR38","doi-asserted-by":"crossref","unstructured":"Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, et al. The multiMiR R package and database: integration of microRNA\u2013target interactions along with their disease and drug associations. Nucleic Acids Res [Internet]. 2014 [cited 2021 Sep 28];42:e133. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4176155\/","DOI":"10.1093\/nar\/gku631"},{"key":"3013_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ygeno.2020.09.041","volume":"113","author":"Z Wicik","year":"2021","unstructured":"Wicik Z, Jales Neto LH, Guzman LEF, Pav\u00e3o R, Takayama L, Caparbo VF, et al. The crosstalk between bone metabolism, lncRNAs, microRNAs and mRNAs in coronary artery calcification. Genomics. 2021;113:503\u201313. https:\/\/doi.org\/10.1016\/j.ygeno.2020.09.041.","journal-title":"Genomics"},{"key":"3013_CR40","doi-asserted-by":"publisher","unstructured":"Holte RC. Very Simple Classification Rules Perform Well on Most Commonly Used Datasets. Mach Learn [Internet]. 1993 [cited 2024 Jul 31];11:63\u201390. Available from: https:\/\/doi.org\/10.1023\/A:1022631118932","DOI":"10.1023\/A:1022631118932"},{"key":"3013_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183435","volume":"12","author":"T Lange","year":"2017","unstructured":"Lange T, Stracke S, Rettig R, Lendeckel U, Kuhn J, Schl\u00fcter R, et al. Identification of miR-16 as an endogenous reference gene for the normalization of urinary exosomal miRNA expression data from CKD patients. PLoS ONE. 2017;12:e0183435. https:\/\/doi.org\/10.1371\/journal.pone.0183435.","journal-title":"PLoS ONE"},{"key":"3013_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17020156","volume":"17","author":"G Rinnerthaler","year":"2016","unstructured":"Rinnerthaler G, Hackl H, Gampenrieder SP, Hamacher F, Hufnagl C, Hauser-Kronberger C, et al. MiR-16-5p is a stably-expressed housekeeping MicroRNA in breast cancer tissues from primary tumors and from metastatic sites. Int J Mol Sci. 2016;17:156. https:\/\/doi.org\/10.3390\/ijms17020156.","journal-title":"Int J Mol Sci"},{"key":"3013_CR43","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ejhf.1119","volume":"20","author":"S De Rosa","year":"2018","unstructured":"De Rosa S, Eposito F, Carella C, Strangio A, Ammirati G, Sabatino J, et al. Transcoronary concentration gradients of circulating microRNAs in heart failure. Eur J Heart Fail. 2018;20:1000\u201310. https:\/\/doi.org\/10.1002\/ejhf.1119.","journal-title":"Eur J Heart Fail"},{"key":"3013_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.amjcard.2017.03.264","volume":"120","author":"R De Rosa","year":"2017","unstructured":"De Rosa R, De Rosa S, Leistner D, Boeckel J-N, Keller T, Fichtlscherer S, et al. Transcoronary concentration gradient of microRNA-133a and outcome in patients with coronary artery disease. Am J Cardiol. 2017;120:15\u201324. https:\/\/doi.org\/10.1016\/j.amjcard.2017.03.264.","journal-title":"Am J Cardiol"},{"key":"3013_CR45","doi-asserted-by":"crossref","unstructured":"Eyileten C, Fitas A, Jakubik D, Czajka P, Mr\u00f3z A, Czajkowska A, et al. Alterations in Circulating MicroRNAs and the Relation of MicroRNAs to Maximal Oxygen Consumption and Intima\u2013Media Thickness in Ultra-Marathon Runners. Int J Environ Res Public Health [Internet]. 2021 [cited 2021 Jul 22];18:7234. Available from: https:\/\/www.mdpi.com\/1660-4601\/18\/14\/7234","DOI":"10.3390\/ijerph18147234"},{"key":"3013_CR46","unstructured":"Gene Set - SIRT6_K562_hg19_1 [Internet]. [cited 2022 Jun 2]. Available from: https:\/\/maayanlab.cloud\/Harmonizome\/gene_set\/SIRT6_K562_hg19_1\/ENCODE+Transcription+Factor+Binding+Site+Profiles"},{"key":"3013_CR47","doi-asserted-by":"publisher","unstructured":"Luo Y-X, Tang X, An X-Z, Xie X-M, Chen X-F, Zhao X, et al. SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity. Eur Heart J [Internet]. 2017;38:1389\u201398. Available from: https:\/\/doi.org\/10.1093\/eurheartj\/ehw138","DOI":"10.1093\/eurheartj\/ehw138"},{"key":"3013_CR48","doi-asserted-by":"publisher","unstructured":"Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell [Internet]. 2006;126:941\u201354. Available from: https:\/\/doi.org\/10.1016\/j.cell.2006.06.057","DOI":"10.1016\/j.cell.2006.06.057"},{"key":"3013_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.21037\/jtd-20-2234","volume":"13","author":"M Zheng","year":"2021","unstructured":"Zheng M, Du X, Zhao L, Sun H, Chen M, Yang X. Elevated plasma Sirtuin2 level predicts heart failure after acute myocardial infarction. J Thorac Dis. 2021;13:50\u20139. https:\/\/doi.org\/10.21037\/jtd-20-2234.","journal-title":"J Thorac Dis"},{"key":"3013_CR50","doi-asserted-by":"publisher","unstructured":"Wang X-X, Wang X-L, Tong M-M, Gan L, Chen H, Wu S-S, et al. SIRT6 protects cardiomyocytes against ischemia\/reperfusion injury by augmenting FoxO3\u03b1-dependent antioxidant defense mechanisms. Basic Res Cardiol [Internet]. 2016 [cited 2024 Sep 23];111:1\u201319. Available from: https:\/\/doi.org\/10.1007\/s00395-016-0531-z","DOI":"10.1007\/s00395-016-0531-z"},{"key":"3013_CR51","doi-asserted-by":"publisher","unstructured":"Li X, Liu L, Jiang W, Liu M, Wang Y, Ma H, et al. SIRT6 Protects Against Myocardial Ischemia\u2013Reperfusion Injury by Attenuating Aging-Related CHMP2B Accumulation. J Cardiovasc Transl Res [Internet]. 2022 [cited 2024 Sep 23];15:740\u201353. Available from: https:https:\/\/doi.org\/10.1007\/s12265-021-10184-y","DOI":"10.1007\/s12265-021-10184-y"},{"key":"3013_CR52","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3233\/CH-201061","volume":"78","author":"S Zhao","year":"2021","unstructured":"Zhao S, Yu L. Sirtuin 1 activated by SRT1460 protects against myocardial ischemia\/reperfusion injury. Clin Hemorheol Microcirc. 2021;78:271\u201381. https:\/\/doi.org\/10.3233\/CH-201061.","journal-title":"Clin Hemorheol Microcirc"},{"key":"3013_CR53","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1161\/CIRCULATIONAHA.110.958033","volume":"122","author":"C-P Hsu","year":"2010","unstructured":"Hsu C-P, Zhai P, Yamamoto T, Maejima Y, Matsushima S, Hariharan N, et al. Silent information regulator 1 protects the heart from ischemia\/reperfusion. Circulation. 2010;122:2170\u201382. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.958033.","journal-title":"Circulation"},{"key":"3013_CR54","doi-asserted-by":"publisher","first-page":"H1602","DOI":"10.1152\/ajpheart.00027.2014","volume":"306","author":"GA Porter","year":"2014","unstructured":"Porter GA, Urciuoli WR, Brookes PS, Nadtochiy SM. SIRT3 deficiency exacerbates ischemia-reperfusion injury: implication for aged hearts. Am J Physiol Heart Circ Physiol. 2014;306:H1602\u20139. https:\/\/doi.org\/10.1152\/ajpheart.00027.2014.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3013_CR55","doi-asserted-by":"publisher","unstructured":"Li Z, Zheng Z, Dai X. SIRT5 induces autophagy and alleviates myocardial infarction via desuccinylation of TOM1. BMC Cardiovasc Disord [Internet]. 2024 [cited 2024 Sep 23];24:1\u201311. Available from: https:\/\/doi.org\/10.1186\/s12872-024-04120-6","DOI":"10.1186\/s12872-024-04120-6"},{"key":"3013_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21524","volume":"9","author":"N Niu","year":"2023","unstructured":"Niu N, Miao H, Ren H. Effect of miR-182-5p on apoptosis in myocardial infarction. Heliyon. 2023;9:e21524. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21524.","journal-title":"Heliyon"},{"key":"3013_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2020.104522","volume":"117","author":"W Lv","year":"2020","unstructured":"Lv W, Jiang J, Li Y, Fu L, Meng F, Li J. MiR-302a-3p aggravates myocardial ischemia-reperfusion injury by suppressing mitophagy via targeting FOXO3. Exp Mol Pathol. 2020;117:104522. https:\/\/doi.org\/10.1016\/j.yexmp.2020.104522.","journal-title":"Exp Mol Pathol"},{"key":"3013_CR58","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7968905","volume":"2017","author":"Y-C Fang","year":"2017","unstructured":"Fang Y-C, Yeh C-H. Inhibition of miR-302 suppresses hypoxia-reoxygenation-induced H9c2 cardiomyocyte death by regulating Mcl-1 expression. Oxid Med Cell Longev. 2017;2017:7968905. https:\/\/doi.org\/10.1155\/2017\/7968905.","journal-title":"Oxid Med Cell Longev"},{"key":"3013_CR59","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1089\/scd.2017.0062","volume":"26","author":"B-C Fu","year":"2017","unstructured":"Fu B-C, Lang J-L, Zhang D-Y, Sun L, Chen W, Liu W, et al. Suppression of miR-34a expression in the myocardium protects against ischemia-reperfusion injury through SIRT1 protective pathway. Stem Cells Dev. 2017;26:1270\u201382. https:\/\/doi.org\/10.1089\/scd.2017.0062.","journal-title":"Stem Cells Dev"},{"key":"3013_CR60","unstructured":"Yang B, Ma S, Wang Y-B, Xu B, Zhao H, He Y-Y, et al. Resveratrol exerts protective effects on anoxia\/reoxygenation injury in cardiomyocytes via miR-34a\/Sirt1 signaling pathway. Eur Rev Med Pharmacol Sci [Internet]. 2016;20:2734\u201341. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27383330"},{"key":"3013_CR61","doi-asserted-by":"publisher","first-page":"10158","DOI":"10.18632\/aging.202778","volume":"13","author":"J Lin","year":"2021","unstructured":"Lin J, Maimaitiyiming A, Chen S, Xiao M, Xian Z. Hypoxia-induced miR-27 and miR-195 regulate ATP consumption, viability, and metabolism of rat cardiomyocytes by targeting PPAR\u03b3 and FASN expression. Aging. 2021;13:10158\u201374. https:\/\/doi.org\/10.18632\/aging.202778.","journal-title":"Aging"},{"key":"3013_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081946","author":"AI Sc\u0103rl\u0103tescu","year":"2022","unstructured":"Sc\u0103rl\u0103tescu AI, Barb\u0103lat\u0103 T, Sima AV, Stancu C, Niculescu L\u0218tefan, Micheu MM. miR-146a-5p, miR-223-3p and miR-142-3p as potential predictors of major adverse cardiac events in young patients with acute ST elevation myocardial infarction-added value over left ventricular myocardial work indices. Diagnostics. 2022. https:\/\/doi.org\/10.3390\/diagnostics12081946.","journal-title":"Diagnostics"},{"key":"3013_CR63","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41401-020-00563-7","volume":"42","author":"Y-Q Ding","year":"2021","unstructured":"Ding Y-Q, Zhang Y-H, Lu J, Li B, Yu W-J, Yue Z-B, et al. MicroRNA-214 contributes to Ang II-induced cardiac hypertrophy by targeting SIRT3 to provoke mitochondrial malfunction. Acta Pharmacol Sin. 2021;42:1422\u201336. https:\/\/doi.org\/10.1038\/s41401-020-00563-7.","journal-title":"Acta Pharmacol Sin"},{"key":"3013_CR64","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2024.0482","author":"M Sohn","year":"2025","unstructured":"Sohn M, Park Y-H, Lim S. Comparative efficacy of initial statin and ezetimibe combination versus statin monotherapy on cardiovascular outcomes in diabetes mellitus: a nationwide cohort study. Diabetes Metab J. 2025. https:\/\/doi.org\/10.4093\/dmj.2024.0482.","journal-title":"Diabetes Metab J"},{"key":"3013_CR65","doi-asserted-by":"publisher","unstructured":"Zhan S, Xia P, Tang M, Liu F, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Libr [Internet]. 2017; Available from: https:\/\/doi.org\/10.1002\/14651858.CD012502","DOI":"10.1002\/14651858.CD012502"},{"key":"3013_CR66","doi-asserted-by":"publisher","unstructured":"The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. 2015 [cited 2025 Jun 10]; Available from: https:\/\/doi.org\/10.1056\/NEJMoa1511939","DOI":"10.1056\/NEJMoa1511939"}],"updated-by":[{"DOI":"10.1186\/s12933-026-03161-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000}}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03013-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-03013-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03013-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:00:39Z","timestamp":1777842039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-025-03013-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3013"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-03013-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The missing rows in Table 3 have been updated","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12933-026-03161-9","URL":"https:\/\/doi.org\/10.1186\/s12933-026-03161-9","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all subjects involved in the study and written informed consent has been obtained from the patient(s) to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"463"}}